The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  New England Journal of Medicine

• Publication date

  2003-12-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA030656PMID 14681504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study)

  2005cited by this paper
• Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.

  2004cited by this paper
• Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.

  2003cited by this paper
• Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.

  2003cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia.

  2002cited by this paper
• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

  2002cited by this paper
• The pathophysiology of benign prostatic hyperplasia.

  2002cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

  2002cited by this paper
• Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

  2002cited by this paper
• Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.

  2001cited by this paper
• Is there a place for combination medical therapy?

  2001cited by this paper
• Does Acute Urinary Retention Respond to Alpha-Blockers Alone?

  2001cited by this paper
• Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

  2000cited by this paper
• Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years

  2000cited by this paper
• THE EFFECT OF FINASTERIDE ON THE RISK OF ACUTE URINARY RETENTION AND THE NEED FOR SURGICAL TREATMENT AMONG MEN WITH BENIGN PROSTATIC HYPERPLASIA

  2000cited by this paper
• Biostatistical Methods: The Assessment of Relative Risks

  2000cited by this paper
• Statistical considerations in the intent-to-treat principle.

  2000cited by this paper
• Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

  1999cited by this paper
• Health-related quality of life associated with lower urinary tract symptoms in four countries.

  1998cited by this paper
• Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.

  1998cited by this paper
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

  1998cited by this paper
• 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study.

  1998cited by this paper
• Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter Study

  1998cited by this paper
• Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound.

  1997cited by this paper
• Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.

  1997cited by this paper
• The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

  1996cited by this paper
• Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.

  1996cited by this paper
• The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

  1996cited by this paper
• Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.

  1996cited by this paper
• A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.

  1995cited by this paper
• Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

  1995cited by this paper
• Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia.

  1995cited by this paper
• A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia.

  1995cited by this paper
• Statistical Methods for Survival Data Analysis

  1994cited by this paper
• The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

  1992cited by this paper
• Indications for treatment of benign prostatic hyperplasia. The American Urological Association Study

  1992cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia.

  1992cited by this paper
• Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations.

  1992cited by this paper
• Goodness-of-Fit Analysis for the Cox Regression Model Based on a Class of Parameter Estimators

  1991cited by this paper
• Explained Residual Variation, Explained Risk, and Goodness of Fit

  1991cited by this paper
• The pathophysiology of benign prostatic hyperplasia.

  1991cited by this paper
• Autonomic receptors in human prostate adenomas.

  1990cited by this paper
• Role of alpha‐adrenergic blockers in the treatment of benign prostatic hyperplasia

  1990cited by this paper
• Properties of the urn randomization in clinical trials.

  1988cited by this paper

• Awareness of benign prostatic hyperplasia among males in the Riyadh region, KSA

  2026influential citation
• Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS.

  2026cites this paper
• Metabolic syndrome as an independent determinant of prostate volume in elderly males over 60 years

  2026cites this paper
• Doxazosin versus tamsulosin for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic literature review and network meta-analysis

  2026cites this paper
• SRD5A2 and emerging therapies in androgen-driven disorders.

  2026cites this paper
• Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing

  2026cites this paper
• Higher Purity of Phosphatidylserine Improves Human Cortical Neuron Function by Modulating SIRT1-PGC-1α Pathways.

  2026cites this paper
• A Multi-Target Phytotherapeutic Approach to Benign Prostatic Hyperplasia: Preclinical Characterization of a PhytoBPH-Mix.

  2026cites this paper
• Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial

  2026cites this paper
• Polymer microspheres in endovascular therapy: From fundamental research to clinical application.

  2026cites this paper
• Gland- and cell-level heterogeneity in the prostate: A narrative review of related diseases

  2025cites this paper
• The practical assessment and management of male lower urinary tract symptoms

  2025cites this paper
• Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis

  2025cites this paper
• Paradigm change in the management of benign prostatic hyperplasia

  2025cites this paper
• Management of patients with lower urinary tract symptoms due to benign prostatic enlargement at risk of progression treated with 5-alpha-reductase inhibitors: examining real-world clinical practice in Spain and Brazil

  2025cites this paper
• Integrated management strategies for benign prostatic hyperplasia

  2025cites this paper
• Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil

  2025cites this paper
• Lower Urinary Tract Symptoms in Men: A Review.

  2025cites this paper
• Letter to the editor for the article “Outcomes of transurethral resection of prostate for benign prostatic obstruction stratified by duration of prior medical therapy”

  2025cites this paper
• Association between lifestyle, multiple chronic conditions, mental health status and the severity of lower urinary tract symptoms/benign prostatic hyperplasia in Chinese elderly

  2025cites this paper
• Role of β and α1-adrenoceptors in pancreatic regulation of glucose homeostasis, apoptosis, and fibrosis in dexamethasone-treated rats: A new insight into β-arrestin2 crosstalk with cAMP, PKA-ERK1/2-CREB, and PKB-FOXO1 signaling pathways

  2025cites this paper
• c‐Kit‐Mediated PI3K/AKT and Wnt/β‐Catenin Signaling Drives Resistance to 5α‐Reductase Inhibitors in Benign Prostatic Hyperplasia

  2025cites this paper
• Voiding symptom severity varies independently from non-adrenergic prostate smooth muscle contractions in patients undergoing surgery for benign prostatic hyperplasia

  2025cites this paper
• Stromal SRD5A2 promotes prostate growth through WNT5A-LEF1-IGF1 signaling in benign prostatic hyperplasia

  2025cites this paper
• Association Between Alpha-Blockers for Benign Prostatic Hyperplasia and Acute Angle-Closure Glaucoma.

  2025cites this paper
• World Journal of Advanced Research and Reviews

  2025cites this paper
• The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia

  2025cites this paper
• Voiding Dysfunction and Parkinson Disease in Geriatric Patients.

  2025cites this paper
• The Impact of Transurethral Enucleation Therapeutic Approach in All-Size Benign Prostatic Obstruction Pathology: From Contemporary Technological Advances to Evidence-Based Clinical Progresses

  2025cites this paper
• Current management of patients affected by benign prostatic hyperplasia: a multi-institutional study from a contemporary large Italian cohort.

  2025cites this paper
• Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

  2025cites this paper
• Stromal SRD5A2 promotes prostate growth through WNT5A-LEF1-IGF1 signaling in benign prostatic hyperplasia.

  2025cites this paper
• Protective effects of Allium ampeloprasum extract against DHT-induced benign prostatic hyperplasia in WPMY-1 cell

  2025cites this paper
• Outcomes of transurethral resection of prostate for benign prostatic obstruction stratified as per duration of prior medical therapy

  2025cites this paper
• Assessment of lower urinary tract symptoms

  2025cites this paper
• Nanogram-Level Green Spectrofluorimetric Method for Simultaneous Quantification of Tadalafil and Silodosin in Pharmaceuticals, Environmental Matrices and Content Uniformity Testing

  2025cites this paper
• Efficacy and safety of high-frequency irreversible electroporation in benign prostatic hyperplasia: a randomized controlled, open-labelled, multicenter clinical study.

  2025cites this paper
• Integrating spatial transcriptomics and single-cell RNA-sequencing reveals epithelial cell alterations in benign prostatic hyperplasia following finasteride treatment

  2025cites this paper
• Do Genetics Predict Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia?

  2025cites this paper
• Current pharmacotheraupeutical options of lower urinary tract symptoms.

  2025cites this paper
• Targeting RBP4-STRA6 retinol signaling disrupts adipose-prostate crosstalk: A novel strategy to suppress basal cell plasticity in androgen deprivation.

  2025cites this paper
• TIAM1 drives prostatic branching phenotype and is a potential therapeutic target for benign prostatic hyperplasia

  2025cites this paper
• Waiting for HoLEP—outcomes when complications arise in the preoperative period

  2025cites this paper
• Five-Year Outcomes of Water Vapor Therapy versus Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial.

  2025cites this paper
• Balloons in Benign Prostatic Hyperplasia: Will They Float? A Comprehensive Review of Prostatic Balloon Prostatoplasty.

  2025cites this paper
• Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction.

  2025cites this paper
• Comparison of dual-agent alpha-blocker treatment with single agent in management of refractory lower urinary tract symptoms

  2025cites this paper
• ICS teaching module on urodynamics for lower urinary tract symptoms in men

  2025cites this paper
• Combination Pharmacotherapy for Benign Prostatic Hyperplasia: Evaluation of Existing Literature on Combination Therapies for Lower Urinary Tract Symptoms Associated with BPH

  2025influential citation
• The predictive value of prostate spherical volume ratio in lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia: a retrospective cohort study

  2025cites this paper
• Efficacy and Safety of Xialiqi for the Treatment of Benign Prostatic Hyperplasia in a Randomized Trial

  2025cites this paper
• Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms.

  2025cites this paper
• Pharmacotherapy for BPH-related LUTS: associations between medication patterns, persistence, and treatment failure

  2025cites this paper
• Dual-Action Beeswax Nanoemulsion for Enhanced Prostate Bioavailability and Synergistic Therapy in BPH and Prostate Cancer

  2025cites this paper
• Clinical comparison of TURP, PVP and holep for small volume BPH

  2025cites this paper
• Molecular Profile and Clinical Associations of Androgen Receptor Coactivators and Structural Genes in Benign Prostatic Hyperplasia and Metabolic Syndrome

  2025cites this paper
• Traitement non interventionnel des symptômes du bas appareil urinaire liés à l’hyperplasie bénigne de prostate : recommandations de bonne pratique clinique du Comité des troubles mictionnels de l’homme

  2025cites this paper
• Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).

  2025cites this paper
• Pine-Extracted Phytosterol β-Sitosterol (APOPROSTAT® Forte) Inhibits Both Human Prostate Smooth Muscle Contraction and Prostate Stromal Cell Growth, Without Cytotoxic Effects: A Mechanistic Link to Clinical Efficacy in LUTS/BPH

  2025cites this paper
• Improving Patient Selection for BPH Medical and Surgical Therapy Through a Deeper Understanding of Prostate Cellular and Molecular Biology.

  2025cites this paper
• Mechanisms of prostatic inflammation-mediated male lower urinary tract symptoms.

  2025cites this paper
• The Sixth Annual Symposium of the Midwest Aging Consortium.

  2025cites this paper
• Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights

  2025cites this paper
• Sexual dysfunction after Rezum therapy for benign prostatic hyperplasia: A scoping review for the current insights and findings

  2024cites this paper
• Impact of Clean Intermittent Self-Catheterization and Indwelling Catheterization on Perioperative Outcomes in Patients with Urinary Retention Undergoing BPH Surgery: A Comparative Monocentric Retrospective Study.

  2024cites this paper
• Evaluation of lower urinary tract symptoms and sexual functions after holmium laser prostate enucleation

  2024cites this paper
• Public Views on Managing Benign Prostatic Hyperplasia-Related Voiding Dysfunction: Potential Applications of Digital Therapeutic

  2024cites this paper
• Prostatic androgen receptor signaling shows an age-related and lobe-specific alteration in mice

  2024cites this paper
• Public Perceptions of Male Hormone Levels and Prostate Health: A Text Mining Analysis of South Korean Media and Online Communities

  2024cites this paper
• Paradigm change in the management of benign prostatic hyperplasia.

  2024cites this paper
• Comparing Patient-Reported Outcomes Following the Minimally Invasive Treatment of Benign Prostatic Hyperplasia (BPH)-Related Lower Urinary Tract Symptoms: Rezum Versus UroLift

  2024cites this paper
• Evaluating the efficacy and safety of Holmium laser enucleation of the prostate in patients with obstructive uropathy attributable to bladder outlet obstruction

  2024cites this paper
• Comparative assessment of attitudes and expectations: Iranian patients versus urologists in the management of benign prostatic hyperplasia

  2024cites this paper
• A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia

  2024cites this paper
• Diterpene glycosides from Fructus Rubi ameliorates benign prostatic hyperplasia in rats through the androgen and TGF-β/Smad signaling pathway.

  2024cites this paper
• Aplicación clínica del sistema de liberación uretral UroLift® en España: consenso sobre el tratamiento de los síntomas del tracto urinario inferior asociados a la obstrucción del flujo urinario por hiperplasia benigna de próstata

  2024cites this paper
• Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting β-catenin pathway

  2024cites this paper
• Clinical application of the UroLift® prostatic urethral lift in Spain: Consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH).

  2024cites this paper
• Urethra-preserving and dorsal capsule fenestration with robot-assisted simple prostatectomy for severe LUTS in small prostate: a case report

  2024cites this paper
• The GG genotype of rs743572 in CYP17A1 gene regulating the decrease of T/E ratio can be an independent risk factor for MetS-BPH: a retrospective cohort study

  2024cites this paper
• Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update

  2024cites this paper
• Comparative efficacy of commercial oral poly-herbal traditional Chinese medicine formulations combined with western medicine in benign prostatic hyperplasia management: a systematic review and network meta-analysis

  2024cites this paper
• Comparing monotherapy with tadalafil or tamsulosin in men with benign prostatic hyperplasia: A case–control study

  2024cites this paper
• Integrating spatial transcriptomics and single-cell RNA-sequencing reveals the alterations in epithelial cells during nodular formation in benign prostatic hyperplasia

  2024cites this paper
• Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2

  2024cites this paper
• Aquablation versus HoLEP in patients with benign prostatic hyperplasia: a comparative prospective non-randomized study

  2024cites this paper
• Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese

  2024cites this paper
• Predictors for surgical treatment in male patients with non-neurogenic lower urinary tract symptoms (LUTS)

  2024cites this paper
• Retención total aguda de orina

  2024cites this paper
• Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing

  2024cites this paper
• Natural Products in the Treatment of Lower Urinary Tract Dysfunction and Infection.

  2024cites this paper
• Measuring the level of interleukins 27, 30 and some biochemical variables in patients with enlarged prostate

  2024cites this paper
• Early investigational agents for the treatment of benign prostatic hyperplasia’

  2024cites this paper
• Is there a best timing for benign prostatic hyperplasia surgery?

  2024cites this paper
• Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development

  2024cites this paper
• Does Delaying Surgical Treatment of BPH Affect Long-Term Outcomes?

  2024influential citation
• Medical Advancements in Benign Prostatic Hyperplasia Treatments

  2024cites this paper
• Cooperation of aquaporin 5 and the adrenergic system in the initiation of birth in rat model

  2024cites this paper
• Bioassay-guided isolation of two antiproliferative metabolites from Pterocarpus indicus Willd. against TGF-β-induced prostate stromal cells (WPMY-1) proliferation via PI3K/AKT signaling pathway

  2024cites this paper
• Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5‐alpha reductase inhibitor resistance

  2024cites this paper